On the other hand, the effective duration of endocrine therapy for non-surgical treatment of ER+HER2- breast cancer is 1.6 years (range 0.5–7.0 years).14) In patients with early breast cancer and heart failure, early breast cancer may emerge as a prognostic factor, even if endocrine therapy is administered. This evidence concerns the gene ERBB2 and heart failure.